£6 million investment from AMR Action Fund extends the existing Series A to £30 million (initial £24M closed January 2022 backed by Boehringer Ingelheim Venture Fund, Evotec SE, and Novo Holdings REPAIR Impact Fund). CTX-187 is the lead clinical candidate in the ABX-01 programme.
About Centauri Therapeutics
UK-based biotech advancing immunotherapeutic antimicrobial programs. Developing CTX-187 (ABX-01 programme), a broad-spectrum immunotherapeutic designed to treat multidrug-resistant Gram-negative bacterial infections using a dual mechanism of action.
Macclesfield, United Kingdom
Read Company ProfileFrequently Asked Questions
What type of funding round did Centauri Therapeutics raise?
Centauri Therapeutics raised a series-a round.
How much did Centauri Therapeutics raise in its series-a?
Centauri Therapeutics raised $6,000,000 GBP in its series-a.
When did Centauri Therapeutics raise its series-a?
Centauri Therapeutics raised its series-a on 2026-02-25.
Who invested in Centauri Therapeutics's series-a?
The investors in Centauri Therapeutics's series-a are: AMR Action Fund, Boehringer Ingelheim Venture Fund, Evotec SE, Novo Holdings REPAIR Impact Fund.
What type of investment was Centauri Therapeutics's series-a?
Centauri Therapeutics's series-a was a equity investment.
How will Centauri Therapeutics use the funds from its series-a?
Centauri Therapeutics plans to use the funds for: Advance CTX-187 through Phase I clinical trials, Prepare CTX-187 for Phase II development, Complete Phase I clinical studies and generate safety data, Support additional research activities to position asset for Phase II.